All In Biotech

Drug Trial Radar · NCT02285088

A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease

A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Feb 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

133

Actual

Start

Dec 2014

Primary completion

Mar 2017

Study completion May 2017

Sponsor

Lead sponsor
Global Blood TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of GBT440 compared with placebo in healthy subjects and subjects with sickle cell disease (SCD).

Conditions

  • Healthy Subjects
  • Sickle Cell Disease

Interventions

  • GBT440Drug

    GBT440 will be administered as oral capsules

  • PlaceboDrug

    Matching placebo will be administered as oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety, as assessed by frequency and severity of adverse events (AEs), and changes in vital signs, 12-lead electrocardiograms (ECGs), and laboratory assessments as compared to baselineTime frame: 30 - 118 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guy's Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.